_Dr. Mohr's lectures_complement[1].lecture.04

_Dr. Mohr's lectures_complement[1].lecture.04 - Complement...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Complement Proteins and Receptors Immune Complexes IgM, IgG Carbohydrates Altered Surfaces Bacteria, LPS C3 Chemotaxins Opsonins Cell Lysis 1 Evolution of Complement • • • Ancient part innate immunity Complement proteins found in the Complement deuterostomes deuterostomes – Echinoderms—Sea urchins – Urochordates—Ascidians – Vertebrates—Jawless and jawed C3, C4, C5 derived from α2-macroglobulin by C3, 2-macroglobulin gene duplication gene 2 Biological Functions of Complement Cell act iv at io n Cell Ly sis Bridge between innate and acquired immunity C3 d CR2 Ag mI g Co m p l e m e n t Opso nizat io n B ly m p ho c y t e 3 General Features • • • • • • • Components synthesized in the liver Heat labile, serum components Reactions are proteolytic cleavages Internal thioester bond in C3 & C4 – ß-cysteinyl-γ -glutaminyl thioester – -Gly-Cys-Gly-Glu-Glu-AsnPathways produce separate C3 & C5 convertases C3 is a key molecule Amplifying and highly regulated 1 423 5678(9)n 4 Reactive thioester bond of C3 5 Classical pathway C2 b C4 C1 Ca2+ C4a C4 b C2 Mg 2 + C4 b 2 a C4 b C2 C3 C3 a C3 b ac t i v a t i n g su r f a c e C1 activated by IgM, IgG, LPS, MBL, C-Reactive protein 6 Structure of C1qrs 7 Activation of C1 C1 s C1 r C1 q C1 s C1 r C1 q Inactive C1q, r & s noncovalently associated One IgM; up to 1000 IgG C3b & C4b binding on surface loosen the C1 complex LPS: either direct binding to C1q or to anti-LPS antibody C1q binds to apoptotic buds and to phagocytic cells 8 C4 C4a C2b C2 Mg 2 + C4 b 2 a C3 C3 a C3 b C1 Ca2+ C4 b C4 b C2 a c t i v a t i n g su r f a c e Calcium very important for stability Activated C1 acts on C4 & C2 Single Activated C1 can generate over 200 C3b Alternative or Properidin Pathway • • • Discovered in early 1950’s by Dr. Louis Discovered Pillemer Pillemer – Isolated a protein that activated the Isolated complement cascade “in midstream” complement – C1, C4, C2 not needed Properidin— Pro-perdo [before loss of C3 Properidin— from consumption] from Validated by discovery of C4-deficient guinea Validated pigs pigs 10 Alternative Pathway • Two mechanisms for activation – C3 tickover pathway–spontaneous hydrolysis of C3 C3 – Amplification pathway—amplifies the classical pathway • • Microenvironment must favor binding of Factor B Initiated by – – – – – – – – – – Gm negative & positive bacteria LPS, pepidoglycans, teichoic acid Fungal cell walls Proteases Tumor cells Heterologous RBCs Anionic polymers (dextan) Pure carbohydrate Classical pathway (amplification loop) Lectin pathway (amplification loop) 11 Alternative pathway: C3 Tickover Pathway P H2O D [C3H2O] C3 C 3bBbP C3 C 3b H20 C3b B B Mg 2 + Ba C3 a C3 b 12 Alternative Pathway: C3 tickover & Amplification Loop 2 C3 P D C3 C3 2 HB 0 D P Mg 2 + B C 3 bBbP C3 b B Ba C3 a C3 b C3* BbP H0 Tickover Pathway a m pli f i ca t i o n l o o p ac t i v a t in g su r f ac e 13 Mannan­Binding­Lectin Pathway C2 b C4 M A SP C4a C2 Mg 2+ C4 b 2a C4 b C2 C3 C3 a C3 b C4 b Ca2+ MB L Mannose ac t iva t ing sur f ace 14 Mannan­Binding­Lectin Pathway P D C3 M A SP Mg 2 + B C 3 bBbP C3 b B Ba C3 a C3 b MBL a m p li f i ca t i o n l o o p ac t i v a t in g su r f ac e 15 Mannan­Binding­Lectin • • • Collectin family of proteins Different forms exist in some species Carbohydrate-recognition domain (CRD) – Binds carbohydrates (CBH) on bacteria, viruses, protozoa – Binds: mannose, glucans, lipophosphoglycans, glucose, Binds: fructose fructose – Distinguishes between self and non-self – Self-CBHs on membrane proteins terminate with sialic acid » Sialic acid not recognized by CRD of MBL • MBL structurally similar to C1q (can also bind to apoptotic buds) MASP • • Family of serine proteases and nonproteases Similar to C1r and C1s 16 Regulation of MBL/MASP • • • No selective regulator of MBL-MASP has No been described been α2-macroglobulin and C1 inhibitor form 2-macroglobulin complexes with MBL-MASP complexes Inhibitors of the classical and alternative Inhibitors pathway will have an effect on the MBL pathway pathway 17 Regulation up to C3 convertases • C1-Inhibitor (C1-INH) – SERPIN family – Covalently binds to activated C1r and C1s Covalently to inhibit activity to – C1-INH prevents spontaneous activation of C1-INH C1 in plasma C1 – Deficiency: Hereditary Angioneurotic Deficiency: Edema Edema – C1-INH also inactivates plasma kallekrein 18 Regulation of the pathway up to the C3 convertases • • C4b2a (classical C3 convertase) C4b2a spontaneous decays to C4b and a derivative of C2a of Decay accelerating factor (DAF) – Bound to membranes by a phosphatidyl inositol Bound glycan anchor glycan – Assembly of C3 convertase (Classical or Assembly Alternative) inhibited Alternative) – Deficiency: Paroxysmal Nocturnal Hemoglobinuria 19 Regulation (cont.) • Amplification loop control – C3bBb is unstable – Factor H binds to C3 & C5 convertases to accelerate decay – Self cell membranes contain regulatory molecules that Self promote the binding of Factor H instead of Factor B to C3b promote » High sialic acid content favors Factor H binding to C3b » Streptococcus (Group B) and Neisseria gonorhoeae put sialic Neisseria acid residues on their surface acid – On non-self structures Factor B has higher affinity for C3b On than Factor H than – C3bH is the substrate for Factor I with the resulting product C3bH P iC3b iC3b D C 3 b B bP B C3 b H H Ba 20 Degradation of C3b and C4b by Factor I B H X C3b CR1 Factor I MCP C3f C3c iC3b Factor I C3dg Membrane Cofactor Protein (MCP) Complement receptor 1 (CR1) MCP C4bBP C4c Factor I C4b H CR1 C4d Factor I deficiency: uncontrolled activation of alternative pathway increased turnover of C3 and consumption of B, H, P Consequence: recurrent bacterial infections 21 Regulation of Classical pathway DAF C1inh C2 b C4 C1 Ca2+ C4a C4 b C2 Mg 2 + C4 b 2 a C4 b C2 C3 C3 a C3 b ac t i v a t i n g su r f a c e spontaneous decay 22 Regulation of the Alternative Pathway: C3 tickover & Amplification Loop C3 CR1 MCP H20 P D DAF & H C3 C3 H20 Mg 2 + H Factor I C 3 bBbP B D P C3 b H Ba C3 a C3 b C3* BbP Tickover Pathway a m pli f i ca t i o n l o o p ac t i v a t in g su r f ac e 23 Membrane Attack Complex C5 C4 b 2a C5a C6 C5b C7 C6 C5b C6 C5b C7 C6 C5b C7 C8 C8 C9 C6 C5b C7 C8 Poly C9 C3 b 24 MAC 25 Membrane Attack Complex http://www.ultranet.com/~jkimball/BiologyPages/C/Complement.html26 Regulation of MAC • • • S-protein S-protein S-protein incorporates into the C5b67 complex at the S-protein stage when C7 is added stage – C8 and C9 can bind but C9 can’t polymerize Very low, low, and high density lipoproteins inhibit the Very formation of the C5b67 complex formation C5a C6 C5b C5 C4 b 2a C7 C6 C5b C6 C5b C7 C6 C5b C7 C8 C8 C9 C6 C5b C7 C8 Poly C9 C3 b 27 • Regulation of MAC Homologous restriction factor (HRF) in membranes of Homologous platelets, neutrophils, monocytes and lymphocytes, erythrocytes – GPI anchor – Binds to C8 & C9 Binds C8 – Becomes incorporated into the MAC – Paroxysmal Nocturnal Hemoglobinuria CD59 (membrane-bound on most nucleated cells CD59 limited amounts on erythrocytes) – GPI anchor – Binds to C8 when it incorporates into the C5b-7 Binds complex complex – Binds to C9 as it folds into the membrane – Paroxysmal Nocturnal Hemoglobinuria – Thrombosis 28 • Regulation of the Membrane Attack Complex HRF C5 C5a C6 C5b C7 S-protein C8 Factor H C4 b 2a C3 b CD59 C6 C5b C7 C6 C5b C7 C8 C6 C5b C7 C8 C6 C5b C9 Poly C9 29 MACs in nucleated cells • • Nucleated cells more resistant to attack – Ion pumps compensate for ionic disturbances – Shedding of MAC (ectocytosis) – Internalization and degradation – CD59 blocks pore assembly – Ectoproteases/ectokinases Killing requires increases in intracellular calcium – Entry through the pore – Release from intracellular stores 30 Other functions of MAC • Neutrophils & macrophages – Synthesis and release of inflam. mediators » Prostaglandins and superoxide anion readical • • – Signaling pathways involve—calcium fluxes, Signaling receptor tyrosine kinases, G-proteins leading to activation of MAPK, NK-κ B (TNFα ) activation Vascular smooth muscle cells, endothelial cells, Vascular mesangial cells mesangial – MAC-stimulated proliferation MAC modulation of apoptosis (promotes and inhibits) 31 Complement Deficiencies • Early component deficiency – C1, C4, C2 – Asymptomatic to pyogenic infections (especially if Asymptomatic there is also Factor B def.) there – Reduced clearance of soluble immune complexes » C3b binds to immune complexes; removed by CR1 • • C3 deficiency – Recurrent pyogenic infections Late component deficiency – C5, C6, C7, C8 – Increased frequency of infections with heavily Increased encapsulated bacteria encapsulated 32 Complement Receptors • CR1 (RBC, phagocytes, lymphocytes, NK cells, dendritic cells, phagocytes, CR1 glomerular cells) glomerular – Binds C3b & C4b – Factor I-induced C3b & C4b degradation » Blocks formation of alternative C3 convertase – Opsonization (immune adherence) – Clearing soluble immune complexes from circulation » CR1 on erythrocytes responsible • CR2 (B lymphocytes) – Binds C3dg, Cdg, iC3b – Part of B lymphocyte activation – Receptor for Epstein-Barr virus CR2 C3 d g Ag mI g B ly m p h o c y t e 33 Complement Receptors • • • CR3 (monocytes, macrophages, NK cells, CR3 neutrophils) neutrophils) – Same as CD11b/CD18—recognizes ICAM-1 – Binds iC3b (opsonic recognition) – Binds to several types of bacteria – Binds immune complexes & enhances their Binds phagocytosis phagocytosis – Binding to iC3b opsonized apoptotic buds Binding downregulates IL-12 and IFN-γ downregulates CR4 (monocytes, macrophages,NK cells) – iC3b – Enhances cell-adhesion & phagocytosis of Enhances immune complexes immune C3a/C4a receptor & C5a receptor 34 • • • • • • • • • References Nonaka, M. Evolution of the complement system. Curr. Opin. Immunol. 13:69Nonaka, Curr. 73, 2001 (on-line) Gadjeva, M. The mannan-binding-lectin pathway of the innate immune Gadjeva, response. Curr. Opin. Immunol. 13: 74-78, 2001 (on-line) Curr. Holers, V. M. Phenotypes of comlement knockouts. Immunopharmacol. 49: 125Holers, Immunopharmacol 131, 2000 (on-line) Zhang, B. The role of complement in inflammation and adaptive immunity. Zhang, Immunol. Rev. 180: 5-15, 2001 Immunol. Muller­Eberhard, H.J. Molecular organization and function of the complement system. Ann. Rev. Biochem. 57:321, 1988 Mold, C. et al. Regulation of complement activation by C­reactive protein. Immunopharmacology 42:23­30, 1999 (Internet Electronic Access) Matsushita, M. The lectin pathway of the complement system. Microbiol. Immunol. 40:887,1996 Liszewski, M. K., et al. Control of the complement system. Adv. Immunol. 61:201, 1996 Würzner, R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Immunopharmacology 42:249­260, 1999 (On­line) Morgan, B. P. Regulation of the complement membrane attack pathway. Crit. Rev. Immunol. 19:173­198, 1999 • 35 References • • • Cole, D. S. and B. P. Morgan. Beyond lysis: how complement Cole, influences cell fate. Clin. Sci. 104: 455-466, 2003 Clin. Turnberg, D, et al. The regulation of the complement system: insights Turnberg, et The from genetically-engineered mice. Mol. Immunol. 40: 145-153, 2003 Mol. Velasco-Velázquez, M. A., et al. Macrophage-Mycobacterium Velasco-Velázquez, et Macrophage-Mycobacterium tuberculosis interactions: role of complement receptor 3. Microbial Microbial Pathogenesis 35: 125-131, 2003 Pathogenesis 36 ...
View Full Document

Ask a homework question - tutors are online